Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia

Diabetes Research and Clinical Practice

Volumn 64, Issue 2, 2004, Pages 137-151

  Durrington, Paul N ^a   Tuomilehto, Jaakko ^b,c   Hamann, Andreas ^d   Kallend, David ^e   Smith, Karen ^e  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^c UNIVERSITY OF HELSINKI   (Finland)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e ASTRAZENECA   (United Kingdom)

Author keywords

Combination drug therapy; Familial combined hyperlipidaemia; Fenofibrate; Rosuvastatin; Type 2 diabetes mellitus

Indexed keywords

FENOFIBRATE; LOW DENSITY LIPOPROTEIN; PLACEBO; ROSUVASTATIN;

ADULT; ARTICLE; ASSOCIATION; CHOLESTEROL BLOOD LEVEL; CONFIDENCE INTERVAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG TOLERANCE; FEMALE; HUMAN; HYPERLIPIDEMIA; INTERMETHOD COMPARISON; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZATION; REDUCTION; STATISTICAL SIGNIFICANCE; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ANTILIPEMIC AGENTS; CHOLESTEROL, LDL; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; MALE; PROCETOFEN; PYRIMIDINES; SULFONAMIDES; TRIGLYCERIDES;

EID: 1842559795     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2003.11.012     Document Type: Article

References (51)

1. Kannel W.B., McGee D.L. Diabetes and cardiovascular disease: the Framingham Study. J. Am. Med. Assoc. 241:1979;2035-2038.
2. Fuller J.H., Shipley M.J., Rose G., Jarrett R.J., Keen H. Coronary-heart-disease risk and impaired glucose tolerance. The Whitehall Study. Lancet. 1:1980;1373-1376.
3. Rosengren A., Welin L., Tsipogrianni A., Wilhelmsen L. Impact of cardiovascular risk factors on coronary heart disease and mortality among middle-aged diabetic men. Br. Med. J. 299:1984;1127-1131.
4. Malmberg M., Ryden L. Myocardial infarction in patients with diabetes. Eur. Heart J. 9:1988;259-264.
5. H. Miettinen, S. Lehto, V. Salomaa, et al., The FINMONICA Myocardial Infarction Register Study Group, Impact of diabetes on mortality after the first myocardial infarction, Diab. Care 21 (1998) 69-75.
6. Haffner S.M., Lehto S., Rönnemaa T., Pyörälä K., Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med. 339:1998;229-234.
7. Durrington P.N. Diabetic dyslipidaemia. Baillières Clin. Endocrinol. Metab. 13:1999;265-278.
8. Manzato E., Zambon A., Lapolla A.et al. Lipoprotein abnormalities in well-treated type 2 diabetic patients. Diab. Care. 16:1993;469-475.
9. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults, Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III), J. Am. Med. Assoc. 285 (2001) 2486-2497.
10. Pyörälä K., Pedersen T.R., Kjekshus J., Faergemann O., Olsson A.G., Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diab. Care. 20:1997;614-620.
11. F.M. Sacks, A.M. Tonkin, J. Shepherd, et al., The Prospective Pravastatin Pooling Project Investigators Group, Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors. The Prospective Pravastatin Pooling Project, Circulation 102 (2000) 1893-1900.
12. Heart Protection Study Collaborative Group, MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial, Lancet 360 (2002) 7-22.
13. Stein E.A., Lane M., Laskarzewski P. Comparison of statins in hypertriglyceridemia. Am. J. Cardiol. 81:1998;66B-69B.
14. Rubins H.B., Sander J.R., Collins D.et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N. Engl. J. Med. 341:1999;410-418.
15. Diabetes Atherosclerosis Intervention Study Investigators, Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study, Lancet 357 (2001) 905-910.
16. Olsson A.G., Pears J., McKellar J., Mizan J., Raza A. Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia. Am. J. Cardiol. 88:2001;504-508.
17. Davidson M., Ma P., Stein E.A.et al. Comparison of effects on low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin versus atorvastatin in patients with type IIa or IIb hypercholesterolemia. Am. J. Cardiol. 89:2002;268-275.
18. Paoletti R., Fahmy M., Mahla G., Mizan J., Southworth H. Rosuvastatin demonstrates greater reduction of low-density lipoprotein cholesterol compared with pravastatin and simvastatin in hypercholesterolaemic patients: a randomized, double-blind study. J. Cardiovasc. Risk. 8:2001;383-390.
19. Olsson A., Southworth H., Wilpshaar J.W. Long-term efficacy and safety of rosuvastatin: results of a 52-week comparator-controlled trial versus atorvastatin. Eur. Heart J. 22(Suppl.):2001;253. (abstract 1410).
20. Brown W.V., Chitra R.R., Zedler B.K., Bays H.E., Hassman H.A. Long-term efficacy and safety of rosuvastatin: results of a 52-week comparator-controlled trial versus pravastatin and simvastatin. Eur. Heart J. 22(Suppl.):2001;270. (abstract 1526).
21. Peters J.R., Quiter E.S., Brekke M.L.et al. The Eating Pattern Assessment Tool: a simple instrument for assessing dietary fat and cholesterol intake. J. Am. Diet. Assoc. 94:1994;1008-1013.
22. Lipid Research Clinics Program, Manual of operations: lipid and lipoprotein analysis, US Department of Health, Education, and Welfare, Washington, DC, 1982, Publication NIH 75-628.
23. Warnick G., Albers J. A comprehensive evaluation of the heparin manganese precipitation procedure for estimating high-density lipoprotein cholesterol. J. Lipid Res. 19:1978;65-76.
24. Steiner P., Freidel J., Bremmer W., Stein E. Standardization of micromethods for plasma cholesterol, triglyceride and HDL-cholesterol with the clinics' methodology. J. Clin. Chem. Biochem. 19:1981;850-851.
25. Myers G.L., Cooper G.R., Winn C.L., Smith S.J. The Centers for Disease Control-National Heart, Lung, and Blood Institute Lipid Standardization Program: an approach to accurate and precise lipid measurements. Clin. Lab. Med. 9:1989;105-135.
26. Albers J.J., Marcovina S.M., Kennedy H. International Federation of Clinical Chemistry Standardization Project for Measurements of Apolipoproteins A-I and B-II: evaluation and selection of candidate reference materials. Clin. Chem. 38:1992;658.
27. D.C. Montgomery, Design and Analysis of Experiments, second ed., Wiley, New York, 1984.
28. American Diabetes Association, Position Statement. Management of dyslipidemia in adults with diabetes, Diab. Care 24 (Suppl. 1) (2001) S58-S61.
29. Haffner S.M. Management of dyslipidemia in adults with diabetes. Diab. Care. 21:1999;160-178.
30. Frost R.J.A., Otto C., Geiss H.C., Schwandt P., Parhofer K.G. Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorrheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia. Am. J. Cardiol. 87:2001;44-48.
31. Aguilar-Salinas C., Gómez-Pérez F.J., Posadas-Romero C. Efficacy and safety of atorvastatin in hyperlipidemic, type 2 diabetic patients. A 34-week, multicenter, open-label study. Atherosclerosis. 152:2000;489-496.
32. Diabetes Atorvastatin Lipid Intervention (DALI) Study Group, The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia. The DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia, Diab. Care 24 (2001) 1335-1341.
33. Knopp R.H., Frohlich J., Jokubaitis L.A., Dawson K., Broyles F.E., Gomez-Coronado D. Efficacy and safety of fluvastatin in patients with non-insulin-dependent diabetes mellitus and hyperlipidemia. Am. J. Med. 96(Suppl. 6A):1994;69S-78S.
34. Tikkanen M.J., Laakso M., Ilmonen M.et al. Treatment of hypercholesterolemia and combined lipidemia with simvastatin and gemfibrozil in patients with NIDDM. A multicenter comparison study. Diab. Care. 21:1998;477-481.
35. Behounek B.D., McGovern M.E., Kassler-Taub K.B., Markowitz J.S., Berman M. A multinational study of the effects of low dose pravastatin in patients with non-insulin-dependent diabetes mellitus and hypercholesterolemia. Clin. Cardiol. 17:1994;556-562.
36. Raskin P., Ganda O.P., Schwartz S.et al. Efficacy and safety of pravastatin in the treatment of patients with type I or type 2 diabetes mellitus and hypercholesterolemia. Am. J. Med. 99:1995;362-369.
37. Brown W.V., Dujovne C.A., Farquhar J.W.et al. Effects of fenofibrate on plasma lipids. Arteriosclerosis. 6:1986;670-678.
38. Frost R.J.A., Otto C., Geiss H.C., Schwandt P., Parhofer K.G. Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia. Am. J. Cardiol. 87:2001;44-48.
39. Bhatnagar D., Durrington P.N., Kumar S., Mackness M.I., Dean J., Boulton A.J. Effect of treatment with a hydroxymethylglutaryl coenzyme A reductase inhibitor on fasting and postprandial plasma lipoproteins and cholesteryl ester transfer activity in patients with NIDDM. Diabetes. 44:1995;460-465.
40. Fruchart J.C., Brewer H.B. Jr., Leitersdorf E. Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease Fibrate Consensus Group. Am. J. Cardiol. 81:1998;912-917.
41. Bilheimer D.W., Grundy S.M., Brown M.S., Goldstein J.L. Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes. Proc. Natl. Acad. Sci. U.S.A. 80:1983;4124-4128.
42. Vega G.L., Grundy S.M. Management of primary mixed hyperlipidemia with lovastatin. Arch. Intern. Med. 150:1990;1313-1319.
43. Broyles F.E., Walden C.E., Hunninghake D.B., Hill-Williams D., Knopp R.H. Effect of fluvastatin on intermediate density lipoprotein (remnants) and other lipoprotein levels in hypercholesterolemia. Am. J. Cardiol. 76:1995;129A-135A.
44. Bakker-Arkema R.G., Davidson M.H., Goldstein R.J.et al. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. J. Am. Med. Assoc. 275:1995;128-133.
45. Arad Y., Ramakrishnan R., Ginsberg H.N. Effects of lovastatin therapy on very-low-density lipoprotein triglyceride metabolism in subjects with combined hyperlipidemia: evidence for reduced assembly and secretion of triglyceride-rich lipoproteins. Metabolism. 41:1992;487-493.
46. Athyros V.G., Papageorgiou A.A., Athyrou V.V., Demitriadis D.S., Kontopoulos A.G. Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Diab. Care. 25:2002;1198-1202.
47. Hunninghake D. HMG-CoA reductase inhibitors. Curr. Opin. Lipidol. 3:1992;22-28.
48. Duell P.B., Connor W.E., Illingworth D.R. Rhabdomyolysis after taking atorvastatin with gemfibrozil. Am. J. Cardiol. 81:1998;368-369.
49. Steiner G. Lipid intervention trials in diabetes. Diab. Care. 23(Suppl. 2):2000;B49-B53.
50. Colhoun H.M., Thomason M.J., Mackness M.I.et al. Design of the Collaborative Atorvastatin Diabetes Study (CARDS) in patients with type 2 diabetes. Diab. Med. 19:2002;201-211.
51. H.B. Brewer, Benefit-risk assessment of rosuvastatin 10 to 40 milligrams, Am J. Cardiol. 92 (4B) 23K-29K.